Navigation Links
Botaneco Announces Launch of Second Generation Oleosome Product
Date:4/14/2008

Natural Hydresia(TM) G2 Offers Enhanced Formulation Flexibility With a

Globally Accepted Preservative System

TSX symbol: SBS

CALGARY, April 14 /PRNewswire-FirstCall/ - Botaneco, a wholly owned subsidiary of SemBioSys Genetics Inc. (TSX: SBS), focused on the development and commercialization of oleosome technology in personal care, OTC and topical pharmaceutical markets, today announced the launch of its second generation oleosome product, Hydresia(TM) G2, at the In-Cosmetics 2008 exposition in Amsterdam. Hydresia(TM) G2, a natural emulsion base, retains all of the functional performance properties of Botaneco's first generation Hydresia(TM) product, while offering formulators the ability to develop products over a broader pH range (3.5-8.5). This will allow for the development of low pH exfoliants and anti-aging products that can provide consumers with the moisturization, skin health and aesthetic benefits that Hydresia(TM) brings to other finished formulations. In addition, Hydresia(TM) G2 uses a new globally accepted preservative system that will expand the use of oleosomes in European and other markets.

"Botaneco is committed to developing ingredients that allow our customers to provide differentiated products that offer both performance and aesthetic benefits to consumers," said Andrew Baum, President and CEO of Botaneco's parent company, SemBioSys. "Hydresia(TM) G2 can be used in moisturizers, hair and skin cleansers, lip care, color cosmetics, skin lighteners, sun care and baby care products just like our first generation Hydresia(TM) product. In addition to these applications, Hydresia(TM) G2 can also be used in products where requirements for low pH have precluded the use of Hydresia(TM). We are excited about the opportunity to expand our product offerings in North America, as well as expanding into European and Asian markets."

Hydresia(TM) G2, as well as the first generation Hyd
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Botaneco obtains $2.4 million in funding from AVAC
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... PARK, Calif., May 27 ForteBio(R), Inc., a leadin...es the development of biotherapeutic and pharmaceu...ed two new assay modules - for high-sensitivity pr...ively - for use on the company,s Octet(R) instrume...a software upgrades and will enable, for the first...
...LL, WA and VANCOUVER, May 27 /PRNewswire-FirstCall...I ) announced today that the Company will hold a l...ade at an OncoGenex hosted reception during the 20...eting (ASCO) on Saturday, May 30, 2009. The webcas...ion, OncoGenex management and guest speakers will ...
...arch has shown that certain marginalized groups i... minorities such as African Americans and Latinos ...l disasters, suffering disproportionate impoverish...udy by UCLA researchers and colleagues has found t... fears and make more behavioral changes based on t...
Other Biology Technology:ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on Its Octet(R) Platform 2OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009 2Disabled and other vulnerable groups more susceptible to terrorism fears 2
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
Breaking Biology News(10 mins):How nutrition affects healthy aging 2Lifelong memories linked to stable nerve connections 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 1Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 2Miami Health Insurance Outlook and Update 54523 1Miami Health Insurance Outlook and Update 54523 2Miami Health Insurance Outlook and Update 54523 3Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 1Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 2Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 3Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 4Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 5Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 6Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 7Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 8Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 9Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 10Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 11Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 12Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 13
...ss announces the latest edition of an essential ...pidly changing fields of clinical medicine. Coveri...nosis, treatment, and prevention, Clinical Virolo...ls about all the medically relevant aspects of thi...tly one of the most dynamic areas of clinical medi...
...helle, NY, March 17, 2009While the Bernard Madoff ...undation, a major benefactor for life science rese...from the scandal as a minor consequence in the lar... & Biotechnology News (GEN). They look at the Mad... global financial environment that has been rocked...
... human papilloma virus (HPV)-infections can lead t...-stage to cervical cancer. Surgical treatment of t... birth in subsequent pregnancies. As the HPV-vacci...ay therefore reduce the number of preterm births. ...of HPV-vaccination. , Cervical cancer developmen...
Other Biology News:New edition available for essential virology reference 2GEN reports on Madoff scandal's impact on the life sciences 2HPV vaccine may prevent preterm births 2
...be gel adaptors, 24 glass tubes (1.5 mm ID, 180 mm... II xi cell and PROTEAN II XL wide-format cell off...ions,* including SDS-PAGE, first- and second-dimen... gradient PAGE as well as high-resolution agarose ...
SVT3-2 Diverter Valve from Bio-Rad
PROTEAN II XL Cell, wide format from Bio-Rad
PROTEAN II xi Cell, 20 cm, without spacers and combs from Bio-Rad
Biology Products: